Pharmacological prevention and treatment of vascular dementia: Approaches and perspectives

被引:52
作者
Baskys, Andrius [1 ]
Cheng, Jin-xiang [2 ,3 ]
机构
[1] Alzheimers Dis Prevent & Treatment Ctr, Orange, CA USA
[2] Fourth Mil Med Univ, Dept Neurosurg, Xijing Inst Clin Neurosci, Xijing Hosp, Xian 710032, Shaanxi Provinc, Peoples R China
[3] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90095 USA
关键词
Antihypertensives; Statins; Acetylsalicylic acid; Memantine; Donepezil; Galantamine; Rivastigmine; Ginkgo biloba; Huperzine A; Folic acid; COGNITIVE DECLINE; GINKGO-BILOBA; DOUBLE-BLIND; EFFICACY; RISK; TOLERABILITY; METAANALYSIS; DONEPEZIL; MEMANTINE; ASSOCIATION;
D O I
10.1016/j.exger.2012.07.002
中图分类号
R592 [老年病学]; C [社会科学总论];
学科分类号
03 ; 0303 ; 100203 ;
摘要
Vascular dementia (VaD) is a common dementing illness. There are no pharmacological agents with a regulatory approval for its treatment or prevention. Review of published clinical trial reports indicates that early treatment of hypertension, a risk factor for stroke, reduces VaD risk and slows progression. However, unlike stroke, treatment of hyperlipidemia with statin class drugs or treatment of blood clotting abnormalities with acetylsalicylic acid do not appear to have an effect on VaD incidence or progression. Pharmacological agents for treatment of Alzheimer's dementia (AD) such as memantine or acetylcholinesterase inhibitors have small positive effects on cognition in VaD, which are likely due to their action on co-existing AD-related neuropathology. Drug development efforts using novel approaches such as patient stratification by their genotype are needed in order to address the increasing need for effective VaD therapeutics. (C) 2012 Elsevier Inc. All rights reserved.
引用
收藏
页码:887 / 891
页数:5
相关论文
共 43 条
[1]  
[Anonymous], CHINESE J CLIN REHAB
[2]  
Areosa SA, 2005, COCHRANE DB SYST REV, V3, DOI DOI 10.1002/14651858.CD003154.PUB4
[3]   Galantamine treatment of vascular dementia: A randomized trial [J].
Auchus, A. P. ;
Brashear, H. R. ;
Salloway, S. ;
Korczyn, A. D. ;
De Deyn, P. P. ;
Gassmann-Mayer, C. .
NEUROLOGY, 2007, 69 (05) :448-458
[4]   Efficacy, safety and tolerability of rivastigmine capsules in patients with probable vascular dementia: the VantagE study [J].
Ballard, C. ;
Sauter, M. ;
Scheltens, P. ;
He, Y. ;
Barkhof, F. ;
van Straaten, E. C. W. ;
van der Flier, W. M. ;
Hsu, C. ;
Wu, S. ;
Lane, R. .
CURRENT MEDICAL RESEARCH AND OPINION, 2008, 24 (09) :2561-2574
[5]  
Baskys A, 2007, CLIN INTERV AGING, V2, P327
[6]   Ginkgo biloba for cognitive impairment and dementia [J].
Birks, Jacqueline ;
Evans, John Grimley .
COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2009, (01)
[7]   Efficacy and tolerability of donepezil in vascular dementia -: Positive results of a 24-week, multicenter, international, randomized, placebo-controlled clinical trial [J].
Black, S ;
Román, GC ;
Geldmacher, DS ;
Salloway, S ;
Hecker, J ;
Burns, A ;
Perdomo, C ;
Kumar, D ;
Pratt, R .
STROKE, 2003, 34 (10) :2323-2330
[8]   The association of antihypertensive medication use with risk of cognitive decline and dementia: a meta-analysis of longitudinal studies [J].
Chang-Quan, H. ;
Hui, W. ;
Chao-min, W. ;
Zheng-Rong, W. ;
Jun-Wen, G. ;
Yong-Hong, L. ;
Yan-You, L. ;
Qing-Xiu, L. .
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2011, 65 (12) :1295-1305
[9]   [+]-Huperzine A treatment protects against N-methyl-D-aspartate-induced seizure/status epilepticus in rats [J].
Coleman, Brian R. ;
Ratcliffe, Ruthie H. ;
Oguntayo, Samuel A. ;
Shi, Xuerong ;
Doctor, Bhupendra P. ;
Gordon, Richard K. ;
Nambiar, Madhusoodana P. .
CHEMICO-BIOLOGICAL INTERACTIONS, 2008, 175 (1-3) :387-395
[10]  
Craig D., 2009, COCHRANE DATABASE SY